Welcome to our dedicated page for Sigyn Therapeutics news (Ticker: SIGY), a resource for investors and traders seeking the latest updates and insights on Sigyn Therapeutics stock.
Sigyn Therapeutics, Inc. (OTCQB: SIGY) is a San Diego-based innovator developing blood purification technologies to combat life-threatening inflammatory conditions. This page serves as the definitive source for tracking SIGY's progress in advancing Sigyn Therapy™ and its complementary platforms targeting chemotherapy optimization and immunotherapy enhancement.
Investors and medical professionals will find timely updates on clinical milestones, regulatory developments, and strategic initiatives. Key focus areas include first-in-human studies for endotoxemia treatment, advancements in ImmunePrep™ antibody optimization, and progress toward Nasdaq listing requirements through recent corporate restructuring.
Our curated news stream covers essential updates including trial protocol finalizations, technology validation results, partnership announcements, and financial disclosures. All content is vetted for accuracy and relevance to SIGY's mission of addressing unmet needs in sepsis management, cancer care, and infectious disease treatment.
Bookmark this page for streamlined access to SIGY's evolving story in medical technology. Check regularly for developments that could influence both patient outcomes and long-term corporate valuation in this emerging therapeutic sector.
Sigyn Therapeutics announces the appointment of Annette Marleau, Ph.D. as Chief Scientific Officer, effective immediately. Dr. Marleau, an expert in blood purification technologies, previously served as Chief Technology Officer at Immunicom, leading R&D for cancer treatment candidates. She has significant achievements, including over $6 million in NIH funding and contributions to FDA-cleared Investigational Device Exemptions. Sigyn's lead product, Sigyn Therapy, is designed for pathogen-associated inflammatory disorders, targeting conditions like sepsis and pneumonia. The company's pipeline also includes ChemoPrep and ChemoPure, aimed at enhancing chemotherapy delivery and reducing toxicity. This leadership change could strengthen Sigyn's position in the competitive biotechnology market.
Sigyn Therapeutics, Inc. (OTCQB: SIGY) announced the filing of its Form 10-K annual report for the year ending December 31, 2022. The Company reported a net loss of approximately $2.9 million, consistent with the previous year's loss. In 2022, Sigyn advanced its Sigyn Therapy™ towards clinical studies, targeting pathogen-associated inflammatory disorders like sepsis and renal disease, and expanded its intellectual property and corporate team. Additionally, a cancer treatment system to enhance chemotherapy delivery was initiated. The Company utilized approximately $1.8 million in net cash for operating activities during the year.
Sigyn Therapeutics (OTCQB: SIGY) reported its third quarter results for 2022, showing a net loss of approximately $727,000 ($0.02 per share), slightly higher than the prior year's loss of $666,000. The company has advanced its operations by commencing trading on the OTCQB Venture Exchange and strengthening its Board of Directors. It is also pursuing first-in-human studies for Sigyn Therapy in End-Stage Renal Disease patients. Key developments include a provisional patent application for a cancer treatment system designed to enhance chemotherapy delivery and reduce toxicity.
Sigyn Therapeutics (OTCQB: SIGY) announced the filing of trademark applications for ChemoPrep and ChemoPure with the USPTO, linked to a patent for enhancing chemotherapy delivery while reducing toxicity. The new system aims to improve tumor site delivery and minimize side effects of chemotherapeutic agents, addressing significant challenges in cancer treatment. Sigyn's technology may also inhibit cancer metastasis related to chemotherapy. The company continues to develop its pipeline, including Sigyn Therapy, targeting unmet health needs.
Sigyn Therapeutics (OTCQB: SIGY) has filed a provisional patent application for a system to enhance chemotherapy delivery and reduce associated toxicity. Currently, less than 5% of chemotherapeutic agents effectively reach tumor sites, leading to toxic side effects and drug resistance. The proposed system aims to improve drug delivery while potentially reducing treatment dosages. CEO Jim Joyce emphasized that this innovation is designed to enhance existing FDA-approved drugs. The company is also advancing its Sigyn Therapy for patients with end-stage renal disease and other serious conditions.
FAQ
What is the current stock price of Sigyn Therapeutics (SIGY)?
What is the market cap of Sigyn Therapeutics (SIGY)?
